Weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk), a GLP-1 receptor agonist, is the first-approved drug for chronic weight management in adults with general obesity or overweight since 2014
Continue for 812 weeks
In some instances, patients have reported less desire to smoke, drink alcohol, use drugs, gamble, compulsively shop, and even bite their nails
This real-world evidence provides a validation of the oral semaglutide data used in the present analysis taken from PIONEER 4, but could not be used to inform a full analysis, as no liraglutide arm was included and use of these treatment effects in a different baseline population is potentially inappropriate
High cardiovascular risk: Patients with multiple risk factors (diabetes, hypertension, high cholesterol, smoking history, family history) likely benefit, though direct trial evidence in lower-risk populations is less extensive
He doesn't drink much and he's not overweight